TransGenic Group

TransGenic Group FCF Growth

The Year-over-Year Free Cash Flow Growth of TransGenic Group (2342.T) as of Nov 5, 2026 is 47.70 %. In the previous year, Year-over-Year Free Cash Flow Growth was 87.64 % — a change of -45.58% (lower).

FCF Growth

47.70 %

YoY

-45.58%

Last updated:

Year-over-Year Free Cash Flow Growth of TransGenic Group is 2026 47.70 % . Year-over-Year Free Cash Flow Growth of TransGenic Group was 2025 87.64 % . It decreases by -45.58% lower compared to the previous year.

The TransGenic Group FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-219.20 JPY
Jan 1, 2020
-60.71 JPY
Jan 1, 2021
487.68 JPY
Jan 1, 2022
16.78 JPY
Jan 1, 2023
-238.11 JPY
Jan 1, 2024
62.10 JPY
Jan 1, 2025
87.64 JPY
Jan 1, 2026
47.70 JPY
The TransGenic Group FCF Growth history
YEARFCF GrowthYoY
47.70 %-45.58%
87.64 %+41.13%
62.10 %-126.08%
-238.11 %-1,519.44%
16.78 %-96.56%
487.68 %-903.35%
-60.71 %-72.31%
-219.20 %-690.47%
37.12 %-438.90%
-10.95 %-110.30%
106.35 %-13.85%
123.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Year-over-Year Free Cash Flow Growth of TransGenic Group is 47.70 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — TransGenic Group

All Key Metrics — TransGenic Group